| Document |
Document Title |
|
WO/2019/224754A1 |
Peptides, peptidomimetics and small molecules, collectively referred to as "decoy peptides", are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These...
|
|
WO/2019/218881A1 |
Disclosed is a method utilizing chromatography in purifying the compound of formula (I).
|
|
WO/2019/220406A1 |
A solid support for use in non-aqueous DNA-conjugated molecule reactions, wherein the support comprises a solid body formed from a plurality of polyethylene glycol units, wherein the solid body includes at least one cationic moiety.
|
|
WO/2019/218904A1 |
Provided are an unnatural amino acid derivative represented by formula (I) (X being a group which binds to arginase; Y being a linking group; and Z being a group which binds to an E3 ubiquitin-protein ligase), a pharmaceutical compositio...
|
|
WO/2019/216651A1 |
A peptide of the present invention, which is composed of a relatively short amino acid sequence, is easily absorbed in the body and excellent in anti-wrinkle efficacy, can promote collagen production, and inhibit aging genes. Therefore, ...
|
|
WO/2019/216466A1 |
The present invention provides novel cyclic dipeptidase. The cyclic dipeptidase according to present invention could be used to produce antibacterial cyclic dipeptide. By using this cyclic dipeptidase it is possible to make a new microor...
|
|
WO/2019/211829A1 |
Compositions and methods for treating malignant gliomas such as glioblastoma are provided, comprising a combination of a peptide conjugate comprising an amino acid sequence derived from the N-terminus of the receptor PAR-1, and the chemo...
|
|
WO/2019/211434A1 |
The present invention relates to dipeptidyl ketoamide m-methoxyphenyl derivatives and their use in the treatment of diseases and conditions associated with elevated calpain activity, such as heart injury caused by infarction, ischemia wi...
|
|
WO/2019/213386A1 |
The disclosure provides proteasome inhibitors that can be used to halt cell division of rapidly dividing cells by preventing the degradation of cell cycle-regulating proteins, such as cyclins, cyclin-dependent kinase inhibitors, and p53....
|
|
WO/2019/208700A1 |
Provided is a novel ingredient having fatigue prevention and recovery effects. This dipeptide is selected from among: (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, D)Pro-(D)Leu, (D)Val-(D)Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp, (D)Ile-(D)Hyp, ...
|
|
WO/2019/208701A1 |
Provided is a novel anti-inflammatory agent. This anti-inflammatory agent has as an active ingredient a dipeptide selected from among: (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, D)Pro-(D)Leu, (D)Val-(D)Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp...
|
|
WO/2019/206853A1 |
The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the ...
|
|
WO/2019/210054A1 |
Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as metho...
|
|
WO/2019/168149A9 |
The present invention addresses the problem of providing: a peptide having an excellent effect to prevent the deterioration in a cognitive function and to improve a cognitive function; and a use of the peptide. In the present invention, ...
|
|
WO/2019/198813A1 |
The present invention addresses the problem of providing a photosensitive cytotoxic agent which can be used for treatments against a wide variety of types of cancer cells, has more superior versatility, and can be used as a therapeutic a...
|
|
WO/2019/197602A1 |
A compound with the formula I: (I) and salts and solvates thereof, wherein: R" is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.
|
|
WO/2019/195080A1 |
Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.
|
|
WO/2019/186497A1 |
The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.
|
|
WO/2019/187534A1 |
The purpose of the present invention is to provide an industrially practicable method for producing reduced glutathione by reducing oxidized glutathione. The method for producing reduced glutathione according to the present invention is ...
|
|
WO/2019/189853A1 |
Provided is a biologically relevant substance to which is bonded a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation in cells. A biologically relevant substance to which is bonded a degradable polyethyl...
|
|
WO/2019/185572A1 |
The present invention provides compounds of formula (I) wherein X, L1 and R1 to R10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the com...
|
|
WO/2019/189733A1 |
The present invention provides an oxidized-glutathione-containing solid composition that can be produced by a simple method, has low deliquescence, and is easy to handle. The present invention pertains to a solid composition containing a...
|
|
WO/2019/186561A1 |
Pharmaceutical compositions comprising specific tetrapeptides, for use in reducing the release or inhibiting the activity of inflammatory cytokines and mediator and treatment of diseases and disorders associated with these cytokines and ...
|
|
WO/2019/181901A1 |
The purpose of the present invention is to provide a compound that acts to inhibit anoikis in cells and enhance cell survival rates, and a compound that induces cell infiltration and enhances cell engraftment. The present invention provi...
|
|
WO/2019/183556A1 |
The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depressio...
|
|
WO/2019/182483A1 |
The invention relates to the field of bioorganic chemistry and concerns novel substrates for determining the enzymatic activity of peptidases. A compound of general formula (1) A-Xaa-Gln-B is proposed as a highly specific and selective s...
|
|
WO/2019/173911A1 |
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-e...
|
|
WO/2019/172210A1 |
[Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof
|
|
WO/2019/172834A1 |
The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...
|
|
WO/2019/166347A1 |
The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility ...
|
|
WO/2019/167034A1 |
Non-antimicrobial compounds, methods and compositions comprising the same for treating medical conditions associated with pathogenic microorganism in a subject, as well as drug-resistant strains thereof, which are effective in immunopote...
|
|
WO/2019/164987A1 |
Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities t...
|
|
WO/2019/161487A1 |
Beef protein was hydrolyzed with each of six commercial enzymes (alcalase, chymotrypsin, trypsin, pepsin, flavourzyme, and thermoase). Electronic tongue measurements showed that the hydrolysates had significantly (p < 0.05) lower bitter ...
|
|
WO/2019/160024A1 |
Provided is a composition for reducing blood pressure and/or reducing neutral fats that has few side effects and is very safe. The composition for reducing blood pressure and/or for reducing neutral fats comprises a casein hydrolysate an...
|
|
WO/2019/160037A1 |
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...
|
|
WO/2019/160916A1 |
Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.
|
|
WO/2019/154053A1 |
Disclosed are a new compound that inhibits IAP and the use thereof. In particular, the present invention relates to a compound which is an IAP inhibitor, or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmace...
|
|
WO/2019/156630A1 |
Disclosed herein is a membrane having less than 15% water content, comprising a modified agarose that is covalently linked to a cell attachment signal such as an amino acid, a peptide and a chemical moiety that cells recognize and intera...
|
|
WO/2019/155464A1 |
The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson's Disease.
|
|
WO/2019/157014A1 |
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schi...
|
|
WO/2019/154151A1 |
The present invention relates to an intermediate compound of formula II-1 or formula II-2 or a salt thereof, and a preparation method therefor. The present invention further relates to a process for synthesizing a compound of formula I b...
|
|
WO/2019/151384A1 |
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...
|
|
WO/2019/151320A1 |
The problem addressed by the present invention is to provide a technique for improving the anticancer effect of ubenimex, especially the anticancer effect on solid cancers. The problem is solved by a compound containing a chain-form stru...
|
|
WO/2019/151137A1 |
The purpose of this invention is to provide a substance which, by being added to food, promotes intracerebral discharge of both noradrenaline and serotonin, thereby preventing cranial brain disease and improving brain function. A specifi...
|
|
WO/2019/147182A1 |
The present invention relates to novel antiatherosclerotic compounds of formula (I), their pharmaceutically acceptable salts, their isomers, and processes for preparing them. The present invention further provides pharmaceutical composit...
|
|
WO/2019/137247A1 |
The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in...
|
|
WO/2019/138355A1 |
To provide a material that can impart excellent bacterial repelling property to a variety of surfaces. A bacterial repelling composition comprising a structure of a self-organized lipid-peptide compound, wherein the lipid-peptide compoun...
|
|
WO/2019/139126A1 |
Provided is a sodium taurocholate cotransporting polypeptide (NTCP) inhibitor which comprises a cyclic peptide having an Xw1-W-Xw2-W structure (Xw1 and Xw2 are each independently T, S, I, L, or V, or N-alkyl amino acids thereof) or a P-X...
|
|
WO/2019/134510A1 |
Disclosed is a short peptide quaternary ammonium salt compound and a use thereof. In particular, disclosed is a type of short peptide quaternary ammonium salt compound or a stereoisomer, polymorph, solvate thereof, or a metabolite, prodr...
|
|
WO/2019/127686A1 |
The present invention relates to a combined ligand, as well as a combined biomimetic chromatography medium, a preparation method therefor, and application thereof. Regarding the combined biomimetic chromatography medium, a hydrophilic po...
|
